摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-1-苄基-3-甲基哌啶 | 82378-86-7

中文名称
4-氨基-1-苄基-3-甲基哌啶
中文别名
N-苄基-3-甲基-4-氨基哌啶
英文名称
1-benzyl-3-methyl-4-aminopiperidine
英文别名
4-amino-1-benzyl-3-methylpiperidine;1-benzyl-3-methyl-piperidin-4-ylamine;1-Benzyl-3-methylpiperidin-4-amine
4-氨基-1-苄基-3-甲基哌啶化学式
CAS
82378-86-7
化学式
C13H20N2
mdl
MFCD09608002
分子量
204.315
InChiKey
MGTFEKWKCLDVNN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.538
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:d9de4f9d7babf53e35c2b9ac5d77847a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氨基-1-苄基-3-甲基哌啶 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 三乙胺 作用下, 以 甲醇二氯甲烷N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 8.0h, 生成 tert-butyl N-methyl-N-[(3S,4R)-3-methylpiperidin-4-yl]carbamate
    参考文献:
    名称:
    [EN] HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS
    [FR] COMPOSÉS D'URÉE ET D'AMIDE HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE JAK2
    摘要:
    The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
    公开号:
    WO2024035627A1
  • 作为产物:
    描述:
    1-苄基-3-甲基-4-哌啶酮乙酸铵 、 sodium cyanoborohydride 作用下, 以 甲醇 为溶剂, 以44 g (92%)的产率得到4-氨基-1-苄基-3-甲基哌啶
    参考文献:
    名称:
    Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
    摘要:
    这项发明涉及新一代三靶向手性广谱抗菌7-取代哌啶喹啉羧酸衍生物,以及它们的光学异构体、二对映异构体或对映异构体,以及它们的药用盐、水合物、前药、多型和伪多型,以及它们的制备、组合物和用途。
    公开号:
    US06878713B2
点击查看最新优质反应信息

文献信息

  • [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DE CCR8
    申请人:MILLENNIUM PHARM INC
    公开号:WO2004058736A1
    公开(公告)日:2004-07-15
    Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I). Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.
    揭示了一种由结构式(I)表示的CCR8抑制剂。还揭示了包括药用载体或稀释剂和由结构式(I)表示的CCR8抑制剂的药物组合物。还揭示了通过向受试者施用CCR8抑制剂来治疗炎症性疾病的方法。
  • [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DU CCR8
    申请人:MILLENNIUM PHARM INC
    公开号:WO2004058709A1
    公开(公告)日:2004-07-15
    Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.
    揭示了由结构式(I)代表的CCR8抑制剂。结构式(I)中的变量在此处描述。还揭示了通过向受试者施用所披露的CCR8抑制剂之一来治疗CCR8介导的疾病,特别是哮喘的方法。
  • 2-oxoimidazole derivatives
    申请人:Banyu Pharmaceutical Co., Ltd.
    公开号:US06258825B1
    公开(公告)日:2001-07-10
    The present invention relates to a compound represented by Formula [I] wherein represents an aromatic carbo- or heterocyclic ring which may have a substituent; Cy represents a mono-, bi- or tricyclic aliphatic carbocyclic group having 3 to 20 carbon atoms, which may have a substituent; represents a mono- or bicyclic aliphatic nitrogen-containing heterocyclic group having 3 to 14 carbon atoms, which may have a substituent; R1 represents a hydrogen atom, a lower alkenyl group, a lower alkynyl group, a cyclo(lower alkyl) group, an amino group, a lower alkylamino group, a di(lower alkyl)-amino group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group or a di(lower alkyl)carbamoyl group, or a lower alkyl group which may have a substituent; and R2 represents a hydrogen atom or a lower alkyl group, a salt or ester thereof, a production process for the same, and an analgesic, a reliever against tolerance to a narcotic analgesic represented by morphine, a reliever against dependence on a narcotic analgesic represented by morphine, an analgesic enhancer, an antiobestic, a drug for ameliorating brain function, a remedy for schizophrenia, a remedy for Parkinsonism, a remedy for chorea, an antidepressant, a remedy for diabetes insipidus, a remedy for polyuria, or a remedy for hypotension, comprising an effective ingredient of the same.
    本发明涉及一种由式[I]表示的化合物 其中 代表可能具有取代基的芳香碳或杂环环;Cy代表具有3至20个碳原子的单、双或三环脂肪环烃基,可能具有取代基; 代表具有3至14个碳原子的单环或双环脂肪氮含杂环基,可能具有取代基;R1代表氢原子、较低的烯基基团、较低的炔基团、环状(较低烷基)基团、氨基、较低烷基氨基、二(较低烷基)-氨基、羟基、较低烷氧基、羧基、较低烷氧羰基、氨基甲酰基、较低烷基氨基甲酰基或二(较低烷基)氨基甲酰基,或可能具有取代基的较低烷基基团;R2代表氢原子或较低烷基基团,其盐或酯,以及其制备方法,以及一种镇痛剂,一种对抗吗啡所代表的麻醉镇痛剂的耐受性的缓解剂,一种对抗吗啡所代表的麻醉镇痛剂的依赖性的缓解剂,一种镇痛增强剂,一种抗肥胖剂,一种改善脑功能的药物,一种治疗精神分裂症的药物,一种治疗帕金森病的药物,一种治疗舞蹈病的药物,一种抗抑郁剂,一种治疗尿崩症的药物,一种治疗多尿症的药物,或一种治疗低血压的药物,包括其有效成分。
  • ACTIVATOR OF ADIPONECTIN RECEPTOR
    申请人:THE UNIVERSITY OF TOKYO
    公开号:US20160214967A1
    公开(公告)日:2016-07-28
    An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y 1 is (CHR 2 ) a — or the like, X is CH or N, R 1 is a C 1-7 alkyl group, m is an integer of 0-4, Y 2 is *—O—CH 2 —CONH—, *—CONH—(CH 2 ) b —CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.
    提供了一种用于激活AdipoR1和AdipoR2的AdipoR激活剂。以下式(1)表示的化合物,其中A是取代或未取代的芳基或类似物,Y1是(CHR2)a—或类似物,X是CH或N,R1是C1-7烷基基团,m是0-4的整数,Y2是*—O—CH2—CONH—,*—CONH—(CH2)b—CO—或类似物,Z是环基团,B可以是Z代表的环基团的取代基,n是0-3的整数。
  • Aryl sulfonamides useful as inhibitors of chemokine receptor activity
    申请人:Dai Mingshi
    公开号:US20050085518A1
    公开(公告)日:2005-04-21
    The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , X, Z, R 2 , X., Ar, n, R 3 and R 4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR8 and accordingly are useful for the treatment of a variety of inflammatory and allergic disorders.
    本发明提供一般式I的化合物:或其药学上可接受的盐,其中R1、X、Z、R2、X.、Ar、n、R3和R4在本文中一般和子集中定义。本发明的化合物是CCR8的抑制剂,因此可用于治疗各种炎症和过敏性疾病。
查看更多